BACKGROUND:  Iron overload disorders include hereditary hemochromatosis and iron-loading anemia. This group of disorders is characterized by excess iron levels in the body due to abnormal iron absorption and metabolism. The CDC estimates that one in every 200-400 Americans may be affected by iron overload disorders. Clinical manifestations may include severe liver diseases, diabetes, heart failure, and other complications that could lead to morbidity and mortality in these patients. Current treatments do not address causes of excess iron levels and are also very burdensome for the patients, such as periodic removal of blood. There is no drug that directly corrects abnormal iron absorption and metabolism in the body.

INNOVATION:  Researchers at UCLA have designed a class of small peptides that regulate iron absorption in the body. These small peptides are based on the natural regulator of iron absorption in humans and possess similar bioactivity. At the meantime, the researchers have also developed a simple bioassay for assessment of bioactivity of small peptides.

POTENTIAL APPLICATIONS 

• Small peptide drugs for treatment of iron overload disorders

ADVANTAGES

• Corrects abnormal iron absorption in the body
• Cheap- and easy- to-make small peptides

DEVELOPMENT-TO-DATE:  Hepcidin small peptide agonists have been synthesized and tested for bioactivity in vitro.

Related Papers (Selected)

• Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. Blood. 2006 Jan 1;107(1):328-33. [more]

Reference: UCLA Case No. 2009-352